Silibinin and paclitaxel cotreatment significantly suppress the activity and lung metastasis of triple negative 4t1 mammary tumor cell in mice

Journal of Traditional and Complementary Medicine

Volumn 2, Issue 4, 2012, Pages 301-311

  Ho, Bing Ying ^a   Lin, Chun Hung ^a,b   Apaya, Maria ^a   Chao, Wen Wan ^a   Shyur, Lie Fen ^a,b,c  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Lung metastasis; Paclitaxel; Silibinin; Synergistic effect; Triple negative breast cancer

Indexed keywords

EID: 84886612584     PISSN: None     EISSN: 22254110     Source Type: Journal    
DOI: 10.1016/S2225-4110(16)30116-X     Document Type: Article

References (33)

1. Candia, B.J., Hines, W.C., Heaphy, C.M., Griffith, J.K., Orlando, R.A., 2006. Protease nexin-1 expression is altered in human breast cancer. Cancer Cell International 6, 16.
2. Chang, H.R., Chen, P.N., Yang, S.F., Sun, Y.S., Wu, S.W., Hung, T.W., Lian, J.D., Chu, S.C., Hsieh, Y.S., 2011. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro , inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Molecular Carcinogenesis 50, 811-823.
3. Chiang, Y.M., Lo, C.P., Chen, Y.P., Wang, S.Y., Yang, N.S., Kuo, Y.H., Shyur, L.F., 2005. Ethyl caffeate suppresses NF-kappaB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin. British Journal of Pharmacology 146, 352-363.
4. Chou, T.C., 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research 70, 440-446.
5. Colombo, V., Lupi, M., Falcetta, F., Forestieri, D., D'Incalci, M., Ubezio, P., 2011. Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemotherapy and Pharmacology 67, 369-379.
6. Cragg, G.M., Grothaus, P.G., Newman, D.J., 2009. Impact of natural products on developing new anti-cancer agents. Chemical Reviews 109, 3012-3043.
7. Deep, G., Agarwal, R., 2010. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer and Metastasis Reviews 29, 447-463.
8. Fayard, B., Bianchi, F., Dey, J., Moreno, E., Djaffer, S., Hynes, N.E., Monard, D., 2009. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Research 69, 5690-5698.
9. Foulkes, W.D., Smith, I.e. , Reis-Filho, J.S., 2010. Triple-negative breast cancer. The New England Journal of Medicine 363, 1938-1948.
10. Heimann, R., Lan, F., McBride, R., Hellman, S., 2000. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Research 60, 298-304.
11. Hoh, C., Boocock, D., Marczylo, T., Singh, R., Berry, D.P., Dennison, A.R., Hemingway, D., Miller, A., West, K., Euden, S., Garcea, G., Farmer, P.B., Steward, W.P., Gescher, A.J., 2006. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clinical Cancer Research 12, 2944-2950.
12. Hou, C.C., Chen, Y.P., Wu, J.H., Huang, C.C., Wang, S.Y., Yang, N.S., and Shyur, L.F. 2007. A galactolipid possesses novel cancer chemopreventive effects by suppressing inflammatory mediators and mouse B16 melanoma. Cancer Research 67, 6907-6915.
13. Hsan, K.M., Chen, C.C., and Shyur, L.F., 2010. Current research and development of chemotherapeutic agents for melanoma. Cancers 2, 397-419.
14. Huang, C.C., Lo, C.P., Chiu, C.Y., Shyur, L.F., 2010. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice. British Journal of Pharmacology 159, 856-871.
15. Kaur, M., Agarwal, R., 2007. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicology and Applied Pharmacology 224, 350-359.
16. Kinghorn, A.D., Pan, L., Fletcher, J.N., Chai, H., 2011. The relevance of higher plants in lead compound discovery programs. Journal of Natural Products 74, 1539-1555.
17. Kohrmann, A., Kammerer, U., Kapp, M., Dietl, J., Anacker, J., 2009. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC cancer 9, 188.
18. Koop, C.E., 2002. The future of medicine. Science 295, 233.
19. Lee, W.L., Shiau, J.Y., Shyur, L.F., 2012. Taxol, camptothecin, and beyond for cancer therapy, in: Shyur, LF and Lau, Allan S.Y. (Eds.), Advances in Botanical Research (volume 62): Recent Trends in Medicinal Plants Research, pp. 133-178.
20. Lin, C.H., Lee, W.L., Shyur, L.F., 2012. An overview of the current development of phytoremedies for breast cancer, in: Cho, William C.S. (Ed.), Materia Medica for Various Cancers (volume 2): Evidence-based Anticancer Complementary and Alternative Medicine. Springer Press, The Netherlands, pp. 47-67.
21. Maxmen, A., 2012. The hard facts. Nature 485, S50-S51.
22. Mitra, S.K., Hanson, D.A., Schlaepfer, D.D., 2005. Focal adhesion kinas: in command and control of cell motility. Nature Reviews in Molecular Cell Biology 6, 56-68.
23. Nieman, M.T., Prudoff, R.S., Johnson, K.R., Wheelock, M.J., 1999. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. The Journal of Cell Biology 147, 631-643.
24. Oka, H., Shiozaki, H., Kobayashi, K., Inoue, M., Tahara, H., Kobayashi, T., Takatsuka, Y., Matsuyoshi, N., Hirano, S., Takeichi, M., et al., 1993. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Research 53, 1696-1701.
25. Ribeiro, J.T., Macedo, L.T., Curigliano, G., Fumagalli, L., Locatelli, M., Dalton, M., Quintela, A., Carvalheira, J.B., Manunta, S., Mazzarella, L., Brollo, J., Goldhirsch, A., 2012. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Annals of Oncology 23, 547-555.
26. Salvinelli, F., Casale, M., Vincenzi, B., Santini, D., Di Peco, V., Firrisi, L., Onori, N., Greco, F., Tonini, G., 2003. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect. Journal of Experimental & Clinical Cancer Research 22, 155-158.
27. Sarkar, F.H., Li, Y., 2006. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Research 66, 3347-3350.
28. Shyur, L.F., Chen, C.H., Lo, C.P., Wang, S.Y., Kang, P.L., Sun, S.J., Chang, C.A., Tzeng, C.M., Yang, N.S., 2004. Induction of apoptosis in MCF-7 human breast cancer cells by phytochemicals from Anoectochilus formosanus . Journal of Biomedical Science 11, 928-939.
29. Siitonen, S.M., Kononen, J.T., Helin, H.J., Rantala, I.S., Holli, K.A., Isola, J.J., 1996. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. American Journal of Clinical Pathology 105, 394-402.
30. Singh, R.P., Gu, M., Agarwal, R., 2008. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Research 68, 2043-2050.
31. Vermeulen, K., Van Bockstaele, D.R., Berneman, Z.N., 2003. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation 36, 131-149.
32. Wellington, K., Jarvis, B., 2001. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15, 465-489.
33. Zhou, L., Liu, P., Chen, B., Wang, Y., Wang, X., Chiriva Internati, M., Wachtel, M.S., Frezza, E.E., 2008. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Research 28, 1119-1127.